A Phase 3 interventional study of Immunoglobulin G (Ig NextGen 16%) in Primary Immune Deficiency, sponsored by CSL Limited. Completed at 9 sites in 2 countries. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2013-06-19.
Sponsored by CSL Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulin G · Primary Immunodeficiency Diseases.
Among the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, this one is the 17th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2008, is one of 20 in phase 3, and was the 7th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:
Azidus Brasil
Ages 2–60
Azidus Brasil
Ages 6–60
Immunoglobulin G: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 3 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 23 · Phase 4 3
First in 2000; this study’s year is marked. 1 started in 2008.
This study's enrollment of 41 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 45 across the 28 interventional studies. Of the 25 that completed or were terminated, 15 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 29 have an industry lead sponsor. The 10 most frequent:
CSL Limited is the lead sponsor of 10 studies on the registry; none are open to participants now.
14 studies in Primary Immunodeficiency Diseases by CSL Limited: none open now, none under way, none of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2008, is one of 9 in phase 3, and was the 5th registered.
CSL Limited’s Primary Immunodeficiency Diseases studies by the year they started, since 2006.
2 of the studies testing Immunoglobulin G in Primary Immunodeficiency Diseases that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04640142Phase 3OctapharmaStudy to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | 2026-11 |
| NCT04944979Phase 3Kedrion S.p.A.Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, from their registry updates:
Among CSL Limited’s 14 in Primary Immunodeficiency Diseases:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study aims to assess the safety and tolerability of subcutaneous Ig NextGen 16% in patients with Primary Immune Deficiency who require Immunoglobulin (Ig) G replacement therapy. Ig NextGen 16% is a liquid immunoglobulin (antibody) preparation.
This is a Phase 3, open label, multi-centre, study for patients requiring Ig replacement therapy. This study is a follow-on study to patients who have completed the CSLCT-SCIG-05-23 clinical trial and wish to continue subcutaneous treatment with Ig NextGen 16% . Additionally, patients currently receiving IVIg with unacceptable adverse reactions or unable to tolerate IVIg as well as patients receiving alternate IG products via the SC route may be enrolled in this study. Patients must not be eligible for any of the Sponsor's ongoing PID studies that are still open to enrolment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Immunoglobulin G (Ig NextGen 16%)
Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
Also known as: Ig NextGen 16%
Rate, Severity and Relatedness of reported Adverse Events
Time frame: Up to Four Years
To monitor patient IgG trough levels while receiving Ig NextGen 16%
Time frame: Up to 4 years
The record gives a start of Apr 2008, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulin G
Primary Immunodeficiency Diseases →